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Abstract
Purpose Aggressive intervention against the bladder
wall during transurethral resection of bladder tumors
(TURBT) causes damage and leakage from blood
vesselstothebladderlumen. Theaimofthisstudywas
to determine whether TURBT could increase the level
of circulating urothelial cells.
Methods Expression of tumor markers, discrimina-
tive for nucleated blood cells and urothelium, was
evaluated by quantitative (q) RT-PCR on RNA
isolated from peripheral blood samples of 51 patients
who underwent TURBT for CcT1c bladder tumors.
Results Four of 14 studied genes, epidermal growth
factor receptor (EGFR), Collagen a-1(I) chain, Mast/
stem cell growth factor receptor (KIT) and CD47,
exhibited signiﬁcant differences in gene expression
between controls and cancer patients. While TURBT
did not signiﬁcantly increase the number of PCR-
positive results of any transcripts, positive RT-PCR
detection for EGFR was signiﬁcantly less frequent on
day 30 compared to results obtained before surgery.
Conclusions Although the results of our study do not
provide evidence for increased tumor cell release into
the peripheral blood after TURBT, they seem to
indicate that EGFR mRNA measurement in the blood
may provide useful information for urologists.
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Introduction
Most bladder cancers (BCa) are derived from the
uroepithelium. Tumors conﬁned to the bladder lining
areregardedasnon-invasive,whilethosethatinvadethe
bladder muscle are invasive. Transurethral resection of
the bladder tumor via a wire loop (TURBT) remains a
standard procedure for the diagnosis of BCa, as well as
for the treatment of non-muscle invasive tumors [1].
While circulating tumor cells (CTCs) in the
peripheral blood have been reported in patients with
several cancer types, including BCa [2–9], it is well
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dures [6, 9] can additionally release dysplastic cells
from the tumor and may affect the levelof CTCs in the
peripheral blood. In turn, dissemination of tumor cells
from locally advanced tumors may signiﬁcantly
increase risk for metastatic disease, although only
limited number of CTCs may colonize distant sites
propagating the metastases.
An optimal method for detecting CTCs should
be sufﬁciently speciﬁc and sensitive with the most
popular methods utilizing polymerase chain reaction
(PCR)-basedanalyses.Theyallowdetectionofexpres-
sion of so-called epithelium-speciﬁc genes, which are
expressed in cancer cells but not in nucleated cells of
the blood. While the detection of mRNA markers
speciﬁc for CTCs by reverse transcription (RT)-PCR
is sensitive, its speciﬁcity may signiﬁcantly differ
depending on the marker. Therefore, marker selection
is considered vital for a proper analysis of CTCs.
Here, we asked the question whether the electrore-
sectionofabladdertumor,whichuseshighpressureof
washing ﬂuid, may induce a spread of cells from
resected tissues into blood stream leading to the
increase level of circulating urothelial cells in the
peripheral blood. To answer it, we used quantitative
RT-PCR to amplify the transcripts of selected genes,
which might be speciﬁc and sensitive indicators of
circulating urothelial cells.
Methods
Patients
A total number of 51 patients (43 men and 8 women;
mean age 67.5 years, range 34–89) with primary or
recurrent urothelial BCa submitted to TURBT
between April 2009 and May 2010 were prospectively
selected for the study. Pathological staging was as
follows: pTa—2 pts (2 patients; 4%), pT1—26 pts (26
patients; 51%), pT2—11 pts (11 patients; 21%), while
in 12 cases (24%) primary tumor stage could not have
been deﬁnitely assessed (pT C1; lack of muscularis
propria in the specimen). The grade of the tumor was
deﬁned as G1, G2 and G3 according to 1973 WHO
classiﬁcation in 8 (16%), 25 (49%) and 18 (35%)
cases, respectively. Details on patient’s age, sex and
pathological diagnosis are given in the Online
Resource 1. The control group consisted of 32 healthy
volunteers, 17 among them were recruited from the
laboratory staff and 15 were selected among individ-
uals who underwent a screening colonoscopy with no
known history of any malignancy. The study protocol
was approved by the Ethics Committee, and all
patients signed informed consent before inclusion.
Urothelial-speciﬁc genes
Literature searching [10–19] allowed selection of the
following genes: uroplakin 2 (UPK2), EGFR, a-type
platelet-derived growth factor receptor (PDGFRA),
Insulin-like growth factor-binding protein 7 (IG-
FBP7), Sorting nexin-16 (SNX16), TP53, KIT, Vas-
cular endothelial growth factor A (VEGFA), CD47
and telomerase reverse transcriptase (TERT), which
expression was reported previously to be highly
speciﬁc and sensitive markers for the detection of
CTCs, including circulating urothelial cells. In addi-
tion, computation of the fold change of transcript
levels between nucleated blood cells and urothelium
was performed in searching for new candidate
biomarkers of CTCs. Appropriate data were imported
from the GSE4251 [20] dataset, which contained gene
expression measurements for blood cells analyzed in
threehealthysubjects,andfromtheGSE3167[21]and
GSE5287 [22] datasets, which contained measure-
ments of normal bladder and various dysplastic
lesions. Datasets were deposited in the Gene Expres-
sion Omnibus [23] database and represented measure-
ments performed on Affymetrix
 Human Genome
U133A and U133A 2.0 platforms, respectively. All
imported measurements were processed with the
GCRMA algorithm [24] and then averaged and sorted
according to minimal fold change between any given
blood cell population (white blood cells, peripheral
blood monocytes and T lymphocytes) and urothelia.
Calculation basing on the highest minima transcript
levels has selected several urothelial-speciﬁc genes
(notshown).Ofthem,fourgenes,COL1A1,COL3A1,
KRT7 and AGR2, were considered as potential
markers of circulating urothelial cells.
RNA studies
Blood samples were collected a day before, immedi-
ately after (1 day) and 3, 7 and 30 days after surgery
by venipuncture into PAXgene Blood RNA Tubes
(QIAGEN) and were kept at –80C until further use.
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123Total RNA from blood samples was isolated using
the PAXgene Blood RNA Kit following the manu-
facturer’s instructions. One lg of RNA was used in
reverse transcription (RT) reactions performed with
the SuperScript II Reverse Transcriptase (Invitrogen
Co., Carlsbad, CA, USA) as per the manufacturer’s
protocol. Quantitative evaluation of cDNA was per-
formed on the ABI 7900HT Real Time PCR system
(Applied Biosystems) using either Sensimix SYBR or
Probe Kit (Bioline, UK) in a 5 ll reaction mixture
containing 2.5 ll2 9 Sensimix, 2 ll cDNA (1:5
dilution) and 200 nM primers or preformulated Taq-
Man Gene Expression Assays (Applied Biosystems).
Q-PCR was carried out at 40 cycles, consisting of 15 s
of denaturation at 95C and hybridization for 1 min at
60C in a 384-well reaction plate. Five serial dilutions
of cDNA from normal colon tissue samples (pool of
cDNAs) were used to construct the standard curves.
The gene expression was regarded as continuous when
ampliﬁcation signal was detected across all the
samples,andrelativetranscriptslevelswerecalculated
using the DDCT method. For the transcripts with
dichotomous expression (positive/negative signal of
expression), we calculated the percent of positive
resultsforagroupofpatients.Oligonucleotideprimers
fortheanalyzedgenetranscripts,usedforSybrGreenI
Dye Assays, were either designed using Primer
Express Software (Applied Biosystems) or taken from
qPrimer Depot database [25] and are listed in Table 1.
The results ofgene expression levels were analyzed
with the Mann–Whitney U test, and differences
between numbers of samples with detectable signal
wereanalyzedusingtheFisher’sexacttest.Pvaluesof
less than 0.01 were considered signiﬁcant.
Results
Selection of potential biomarkers
Gene expression was analyzed using qRT-PCR with
40 ampliﬁcation cycles using either pairs of designed
primerswith SYBRGreen chemistryor TaqManGene
Expression Assay. To determine the potential speci-
ﬁcity of both literature- and microarray-selected genes
(listed in the ‘Methods’ section), analyses of expres-
sion were ﬁrstly conducted on RNA isolated from
blood samples collected from two groups of control
subjects: 17 controls recruited from the laboratory
staff and 15 controls from whom blood samples were
taken immediately before colonoscopy.
As shown in Table 1, while the expression of 8 of
14 studied genes was found for most control blood
samples, detectable signals of EGFR, COL1A1 and
AGR2 could be determined for only a few control
samples. Expression of TERT, TP53, SNX16 and
VEGFA signiﬁcantly varied between series of PCR
assays due to very low signal level (detectable above
37 cycles of ampliﬁcation), which led to low repro-
ducibility of results. In addition, qRT-PCR analyses
revealed signiﬁcant differences in expression of two
genes between the two control groups. The detectable
signal of UPK2 mRNA was found in one of 17 control
bloodsamplesobtainedfromlaboratory staffandin14
of 15 blood samples collected immediately before
colonoscopy (P = 8,551E-07). Also, the relative
levels of KIT expression were signiﬁcantly higher
(P = 4,55E-06) in blood samples collected in
healthy controls before colonoscopy compared to
laboratory staff controls.
Biomarkers differentiating between healthy
controls and bladder cancer patients
Then, we compared gene expression estimated in
blood samples collected from BCa patients a day
before TURBT and from control individuals. The
expression level of CD47 was signiﬁcantly higher in
blood samples collected from BCa patients compared
to both control groups (P = 1.19E-12 and
P = 1.83E-12, respectively), and the expression of
KIT was signiﬁcantly higher compared to controls
selected only from laboratory staff (P = 3.68E-03).
Among genes with expression detected in a limited
number of blood samples, mRNAs of EGFR and
COL1A1 were found signiﬁcantly more frequently in
cancerpatientsamplesthanincontrols(P = 0.000605
and P = 0.006737, respectively). Expression of
AGR2 was not detectable in blood samples from
cancer patients. Expression of all other genes selected
for this study did not differentiate the bladder cancer
patient group from healthy controls.
Histological grading is an important prognostic
factor for bladder tumors, especially for prediction of
progression [1, 26, 27]. Superﬁcial low-grade cancers
frequently recur, but they exhibit a minimal risk for
progression, while high-grade, locally advanced
tumors often metastasize and therefore, result in poor
Int Urol Nephrol (2012) 44:761–767 763
123clinical outcome [28]. However, we could not ﬁnd any
correlation between the level of expression or the
PCR-positive-signal frequency of any of the studied
markers for CTCs with the grading of bladder tumor
(not shown).
Blood biomarkers levels after TURBT
To detect whether TURBT may inﬂuence the level of
the circulating urothelial cells, in the peripheral blood,
expressionofallstudiedmarkergenes wasanalyzedin
blood samples collected before and 1, 3, 7 and 30 days
after surgery. Four genes (Table 2) exhibited signif-
icant differences in gene expression between controls
and cancer patients found at least at one time point
after TURBT. While TURBT did not signiﬁcantly
increase the number of PCR-positive results of
any transcripts, a positive EGFR expression was
signiﬁcantly less frequent (P = 0.0021) at 30th day
compared to results obtained on day 0.
Discussion
The detection of CTCs has been demonstrated in the
blood of patients with colon, breast, prostate and other
cancers [4–8]. Some of these markers may speciﬁcally
detect circulating urothelial cells. Most reported
studies employed RT-PCR-based analyses, and while
they generally exhibited well-documented sensitivity,
their speciﬁcity might be questionable.
Analysis of epithelial-speciﬁc mRNAs by a qRT-
PCR is a sensitive technique that allows CTCs identi-
ﬁcationintheperipheralcirculation.However,because
of the limited speciﬁcity of these assays, leading to
both false-positive and false-negative results, proper
Table 1 Number of positive qRT-PCR results for mRNAs
selected from published reports (genes 1–10) or from analysis
of microarray data (genes 11–14) in blood samples collected
from two groups of controls: group A—healthy subjects
recruited from the laboratory staff; group B—healthy subjects
with no illnesses or known history of malignancy selected
among individuals who underwent a screening colonoscopy
Candidate markers No. Gene name Control subjects qRT-PCR primers sequences 50 C 30
(Sybr Green chemistry) or
Taqman Gene Expression assay ID Group A
(n = 17)
Group B
(n = 15)
Literature-based 1 EGFR 0 0 Hs01076092_m1
2 UPK2 1 14 Hs00171854_m1
3 CD47 17 15 Hs00179953_m1
4 IGFBP7 17 15 F:TGCGAGCAAGGTCCTTCCATA
R:ATGAGGACAGGTGTCGGGATTC
5 SNX16 17 15 F:AGTCCTCTGCACTTGAGGTTGA
R:CAGCATCATATGCCACTTCTGCT
6 TP53 17 15 F:TTGCAATAGGTGTGCGTCAGA
R:AGTGCAGGCCAACTTGTTCAG
7 KIT 17 15 F:GGCGACGAGATTAGGCTGTT
R:CATTCGTTTCATCCAGGATCTCA
8 PDGFRA 17 15 F:GGCATTCTTTGCAATACTGCTTAA
R:CATCTGCCGATAGCACAGTGA
9 TERT 16 14 Hs99999022_m1
10 VEGF 17 15 F:AGGAGGAGGGCAGAATCATCA
R:CTCGATTGGATGGCAGTAGCT
Microarray-based 11 COL1A1 1 0 Hs00164004_m1
12 COL3A1 2 7 Hs00943809_m1
13 KRT7 5 8 Hs00559840_m1
14 AGR2 1 0 Hs00180702_m1
 Forward primer sequence;  Reverse primer sequence
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123selection of mRNA markers strongly determines the
ﬁnal results of the study. Therefore, the study started
withtheidentiﬁcationofurothelium-speciﬁc genes.As
a result, circulating EGFR mRNA-positive cells were
found in 27% of blood samples collected from bladder
cancer patients and in none of the control blood
samples. Also, positive RT-PCR signals for COL1A1
and CD47 mRNAs were found signiﬁcantly more
frequent and at higher levels, respectively, in blood
samples collected from cancer patients compared to
controls. EGFR and COL1A1 are not expressed in
hemopoietic cells [20], while expression of CD47
seems to be signiﬁcantly lower in those cells compared
to expression in epithelial cells. Thus, from potential
molecularmarkersselectedforouranalyses,expression
of only few genes exhibited the desired speciﬁcity.
It should however be noted that the results of our
statistical analysis may be underestimated. Compari-
sons utilizing only qualitative information in datasets
of moderate size, such as employed in this study,
require large relative frequency differences to con-
clude signiﬁcant group bias. Moreover, results are
susceptible even to single sample readout alteration.
For example, when one group features 20/31 pos/neg
ratio, there is no possibility of proving signiﬁcantly
lower pos/neg proportions in other groups using 17
samples (assuming P value\0.01). Only a 14/3 (or
higher)pos/negratioissigniﬁcantinthatgroup(Fisher
test, signiﬁcance level = 0.01, Online Resource 2).
Previous studies have reported EGFR expression in
30–50% of bladder tumors [29], and the presence of
EGFR transcript inperipheral blood was proposed as a
marker forcirculatingBCa celldetection [13].Astudy
by De Luca et al. [30], which detected EGFR-
expressing cells in the blood of lung, breast and colon
cancer patients, suggests that this assay rather may be
used in detecting cancer cells of epithelial origin than
different carcinoma types. Nevertheless, the combi-
nation of several markers could increase speciﬁc
cancer type detection, and such molecular indicators
were also proposed for BCa.
Expression of UPK2 was found to be highly
speciﬁc to the uroepithelia [31, 32] and was suggested
as a highly speciﬁc but not sensitive blood marker for
CTCs in bladder cancer patients [3]. However, in our
study, a standard bowel preparation by polyethylene
glycol (Fortrans) followed by a cleansing phosphate
enema 30 min before the colonoscopy signiﬁcantly
affected expression of UPK2 and KIT in blood
samples from healthy subjects. Therefore, bowel
preparation before colonoscopy may release epithelial
cells into circulation or activate transcription of
epithelia-speciﬁc genes in hemopoietic cells or both.
An optimal method for detecting CTCs should be
not only sufﬁciently speciﬁc but also sensitive enough
to deﬁne the relatively low number of tumor cells in
blood samples. Recently, the most popular methods
employed for analyzing CTCs have used PCR
Table 2 Percent of positive qRT-PCR signal for EGFR, COL1A1 and COL3A1 mRNAs and relative expression levels of KIT and
CD47 in blood samples collected from controls and patients treated for bladder tumors
Controls Days after TURBT (P values)
Before 1 3 7 30
Positive signal of expression (percent)
EGFR 0% 27%
(0.0006)
20%
(0.005)
14%
N.S.
10%
N.S.
4%
N.S.
COL1A1 3% 27%
(0.007)
45%
(0.0004)
25%
(0.007)
36%
(0.0004)
23%
N.S.
COL3A1 28% 40%
N.S.
38%
N.S.
30%
N.S.
36%
N.S.
22%
N.S.
Relative expression levels
KIT 0.061 0.231
(8.66E-07)
0.265
(0.003)
0.224
(1.43E-06)
0.258
(1.70E-06)
0.291
(1.23E-06)
CD47 0.020 0.279
(2.71E-08)
0.233
(1.09E-08)
0.264
(1.30E-07)
0.219
(1.10E-08)
0.200
(8.46E-08)
 Control group consisted of 17 healthy volunteers selected from laboratory staff
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123detection of so-called epithelium-speciﬁc genes,
which are potentially expressed in CTCs but not in
blood nuclear cells. However, most analyzed tran-
scripts exhibited variability in RT-PCR signals that
hampered their recognition as speciﬁc markers for
CTCs. This variability may be caused by many
reasons. Although qRT-PCR greatly increases the
sensitivity of mRNA detection, its usefulness as a
speciﬁc method for CTC detection, speciﬁcally in
blood specimens, is questionable. A low PCR signal
signiﬁcantlydecreasesthereproducibilityofinter-and
intra-measurement results. In addition, PCR-based
methods may detect both malignant and non-malig-
nant epithelial cells circulating in the blood. Both cell
types may be released into the blood due to undeﬁned
reasons and with undeﬁned intervals [3], leading to
their inconsistent presence in the circulation. For these
reasons, the existing PCR-based methods of detecting
CTCs have limited usefulness for clinical use.
Despite the above-mentioned reservations, we can
drawtwoconclusionsfromourstudy:(1)expressionof
EGFR in the blood may be considered to be a speciﬁc
marker for the detection of circulating urothelial cells
and its mRNA measurement in the blood may provide
useful information for urologists; (2) the results of this
study do not provide evidence for increased tumor cell
release into the peripheral blood after TURBT.
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